Understanding the Impact of Gastric Cancer Glycolytic Reprogramming

Gastric cancer continues to be a formidable challenge for oncologists in India, often presenting at advanced stages where surgical options are limited. While immune checkpoint blockade has revolutionized treatment for many malignancies, only a small fraction of gastric cancer patients achieves a durable response. This limited efficacy suggests that non-genomic barriers within the tumor microenvironment significantly hinder antitumor immunity. Recent research highlights gastric cancer glycolytic reprogramming as a primary culprit in this resistance. By shifting their metabolism toward aerobic glycolysis, tumor cells consume vast amounts of glucose and produce excessive lactate. This metabolic shift does not merely support rapid cell proliferation; it actively creates a hostile niche for immune cells. Consequently, understanding these metabolic interactions is crucial for developing the next generation of precision therapies. By addressing the metabolic landscape, clinicians may finally overcome the immunosuppressive barriers that render many tumors refractory to standard immunotherapy protocols.

Molecular Drivers Behind the Metabolic Shift

The transition to a glycolysis-heavy state is driven by a complex network of oncogenic signaling and environmental cues. Hypoxia-inducible factor-1α (HIF-1α) serves as a central orchestrator, upregulating the expression of essential glycolytic enzymes even in the presence of oxygen. Furthermore, the activation of the phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) pathways further accelerates this metabolic transition. These molecular drivers increase the production of hexokinase 2 and pyruvate kinase M2, which catalyze the initial and final steps of the glycolytic pathway. Additionally, monocarboxylate transporters facilitate the rapid efflux of lactate, preventing intracellular acidification while poisoning the surrounding microenvironment. Specifically, noncoding RNA networks act as fine-tuners, modulating the expression of these enzymes to ensure the tumor maintains a competitive metabolic advantage. These integrated signaling hubs ensure that gastric cancer cells remain metabolically dominant, effectively starving infiltrating immune cells of the nutrients they need to mount an effective defense.

The Immunosuppressive Power of Lactate Accumulation

Lactate was once viewed simply as a metabolic waste product of the Warburg effect, but we now recognize it as a potent bioactive mediator. Within the tumor niche, high lactate concentrations impair the differentiation of dendritic cells, which are vital for presenting tumor antigens to the immune system. Moreover, lactate accumulation weakens the activity of natural killer cells and cytotoxic T-cells, which are the primary effectors of the antitumor response. This metabolic environment also promotes the polarization of macrophages toward a pro-tumor M2-like phenotype. Through G protein-coupled receptor 81-dependent signaling and epigenetic changes like histone lactylation, lactate effectively rewires the immune compartment to support tumor growth rather than destruction. These changes create a self-sustaining cycle of immunosuppression that is incredibly difficult to break with conventional checkpoint inhibitors. Consequently, the high-lactate microenvironment acts as a metabolic shield, protecting the tumor from being recognized and eliminated by the patient’s own immune system.

Stromal Contributions to the Glycolytic Niche

The tumor microenvironment is not composed of malignant cells alone; cancer-associated fibroblasts and mesenchymal stem cells play critical roles in reinforcing the glycolytic state. These stromal cells often engage in metabolic crosstalk with the tumor, a phenomenon sometimes referred to as the reverse Warburg effect. In this scenario, fibroblasts undergo their own glycolytic reprogramming and shuttle lactate directly to tumor cells, which can then use it for oxidative phosphorylation or signaling. Furthermore, these cells secrete cytokines and remodel the extracellular matrix, creating physical and chemical barriers to T-cell infiltration. Exosome-mediated transfer of noncoding RNAs from the stroma to the tumor further boosts the expression of glycolysis-promoting genes. These complex interactions generate spatially organized niches characterized by abnormal angiogenesis and poor immune cell presence. By working in tandem with the tumor cells, the surrounding stroma ensures that the metabolic environment remains favorble for cancer progression while remaining hostile to therapeutic interventions.

Diagnostic Innovations and Patient Stratification

Accurately identifying which patients possess a high-glycolysis phenotype is essential for personalized medicine. Fluorine-18 fluorodeoxyglucose positron emission tomography, commonly known as FDG PET/CT, is a valuable tool for visualizing glucose uptake in vivo. Beyond simple imaging, radiomics allows for the extraction of quantitative data that can predict the metabolic profile of a tumor based on its texture and heterogeneity. Researchers are also developing gene signatures related to glycolysis and lactylation to categorize patients into distinct immunometabolic subtypes. Specifically, exosomal biomarkers found in the blood may provide a non-invasive way to monitor dynamic metabolic changes during the course of treatment. Such diagnostic frameworks allow clinicians to predict which patients are likely to be refractory to standard immune checkpoint blockade. By integrating these metabolic monitoring tools into clinical practice, doctors can better stratify patients and guide the rational selection of combination therapies designed to target both the immune and metabolic facets of the disease.

Emerging Therapeutic Strategies and Future Directions

Targeting the metabolic vulnerabilities of gastric cancer represents a promising new frontier in oncology. Current research is focusing on inhibitors of lactate dehydrogenase A and monocarboxylate transporter 4 to reduce lactate production and export. Additionally, drugs that target the HIF-1α and mTOR pathways are being evaluated for their ability to reset the metabolic clock of the tumor microenvironment. Epigenetic regulators that modulate histone lactylation also offer a novel way to reverse the immunosuppressive effects of lactate. Repurposing existing metabolic drugs, such as those used for diabetes or lipid disorders, in combination with PD-1/PD-L1 inhibitors is another strategy currently under investigation. These combination therapies aim to strip away the metabolic shield of the tumor, making it more susceptible to the rejuvenated immune response. As clinical trials progress, the hope is that these interventions will provide new life for patients with metabolically protected, refractory disease. Moving forward, viewing gastric cancer through this immunometabolic lens will be essential for overcoming the barriers to durable clinical success.

Frequently Asked Questions

How does lactate influence immune cell function in gastric cancer?

Lactate acts as a potent signaling molecule that reshapes the immune landscape within the tumor. It impairs the ability of dendritic cells to prime T-cells and reduces the killing capacity of natural killer cells. Furthermore, high lactate levels induce epigenetic changes like histone lactylation, which polarizes macrophages into a pro-tumor M2 phenotype. This creates a deeply immunosuppressive environment that prevents the immune system from successfully attacking the gastric cancer cells.

What are the primary molecular drivers of gastric cancer glycolytic reprogramming?

The metabolic shift toward glycolysis is primarily driven by oncogenic signaling through the PI3K/Akt/mTOR pathway and the stability of Hypoxia-inducible factor-1α (HIF-1α). These pathways upregulate critical enzymes like hexokinase 2 and pyruvate kinase M2, alongside lactate transporters such as MCT4. Additionally, noncoding RNA networks further refine these processes, ensuring the tumor cells maintain high glycolytic flux to support their rapid growth and survival under low-oxygen conditions.

Can metabolic targeting improve the efficacy of immune checkpoint inhibitors?

Yes, targeting metabolism is a promising strategy to overcome resistance to immunotherapy. By using inhibitors against LDHA or monocarboxylate transporters, clinicians can reduce the accumulation of immunosuppressive lactate. This helps to "normalize" the tumor microenvironment, making it more hospitable for infiltrating T-cells. When combined with PD-1/PD-L1 blockade, these metabolic interventions can potentially strip away the tumor’s metabolic protection and lead to more durable clinical responses in refractory patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. It is not a substitute for professional medical diagnosis, treatment, or advice. Always seek the guidance of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Zhang B et al. Glycolysis‑driven immunosuppression in gastric cancer: Metabolic crosstalk between tumor cells and the immune microenvironment (Review). Int J Oncol. 2026 Sep undefined. doi: undefined. PMID: 42429073.

Shan ZS et al. Harnessing glycolysis in gastric cancer: molecular targets, therapeutic strategies, and clinical horizons. Front Immunol. 2025 Sep 04;16:1628937. doi: 10.3389/fimmu.2025.1628937.

Liu Y et al. Lactate and gastric cancer immunotherapy from regulatory mechanisms to therapeutic strategies: a critical review. PMC. 2025 Nov 14. doi: 10.1186/s40001-025-03383-9.